Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Adjunctive dual biologic therapy for persistent nasal symptoms in eosinophilic granulomatosis with polyangiitis (EGPA)

Title: Adjunctive dual biologic therapy for persistent nasal symptoms in eosinophilic granulomatosis with polyangiitis (EGPA)
Authors: Gramellini, Giulia; Borin, Marco; Lazzeroni, Matteo; Dragonetti, Alberto Giulio; Capaccio, Pasquale; Mevio, Niccolò; Schroeder, Jan Walter Volk
Contributors: G. Gramellini; M. Borin; M. Lazzeroni; A.G. Dragonetti; P. Capaccio; N. Mevio; J.W.V. Schroeder
Publisher Information: W.B. Saunders; Elsevier
Publication Year: 2026
Collection: The University of Milan: Archivio Istituzionale della Ricerca (AIR)
Subject Terms: Benralizumab; CRSwNP; Dupilumab; mepolizumab; EGPA; Settore MEDS-18/A - Otorinolaringoiatria
Description: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic vasculitis frequently involving both upper and lower airways, commonly associated with severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Although anti-IL-5/IL-5R biologics such as mepolizumab and benralizumab are established therapies for maintaining systemic remission, a subset of patients continues to experience refractory sinonasal symptoms. We report two EGPA cases with well-controlled systemic disease under anti-IL-5/IL-5R therapy but persistent uncontrolled CRSwNP, who were treated with add-on dupilumab. Both patients demonstrated substantial improvement in sinonasal outcomes, as reflected by reductions in SNOT-22 and nasal polyp scores, alongside maintenance of systemic remission (BVAS = 0). These findings highlight the potential role of dual biologic therapy targeting distinct inflammatory pathways in selected EGPA patients with refractory CRSwNP. Careful patient selection and close multidisciplinary monitoring are essential to ensure safety and optimize efficacy. Further studies are warranted to confirm long-term effectiveness and safety profiles.
Document Type: article in journal/newspaper
Language: English
Relation: info:eu-repo/semantics/altIdentifier/pmid/41343954; info:eu-repo/semantics/altIdentifier/wos/WOS:001638184600002; volume:47; issue:1; firstpage:1; lastpage:2; numberofpages:2; journal:AMERICAN JOURNAL OF OTOLARYNGOLOGY; https://hdl.handle.net/2434/1232682
DOI: 10.1016/j.amjoto.2025.104761
Availability: https://hdl.handle.net/2434/1232682; https://doi.org/10.1016/j.amjoto.2025.104761
Rights: info:eu-repo/semantics/closedAccess ; license:Nessuna licenza ; license uri:iris.PRI01
Accession Number: edsbas.8931DFE1
Database: BASE